Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Study finds colonoscopy safe for Chinese children

Colonoscopy in children is a highly specialized procedure which is not often performed in the Chinese population. Data of its safety and diagnostic yield in Chinese children is scarce. One of the most common indications for colonoscopy in children of western countries is investigation and follow-up assessment for inflammatory bowel disease which is uncommon in Chinese children. It has recently been reported that there is increasing occurrence of childhood inflammatory bowel disease in western countries. It is, however, unknown whether a similar increase happens in Chinese children.

27 Mar 2010

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Standard HCV therapy less effective in urban minority patients: Study

A recent study confirms that the standard hepatitis C therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

26 Mar 2010

New therapies increase survival rates in post-transplant liver cancer patients

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

25 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

Celsion Corporation today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology 2010 Annual Meeting.

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Researchers find some similarities between SPN and PET

Solid-pseudopapillary neoplasm (SPN) of the pancreas is relatively rare. There are some similarities between SPN and pancreatic endocrine tumor (PET), especially the non-functioning ones, in clinical and pathological manifestations.

18 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

Warning that "systemic underfunding of the Centers for Disease Control's Division of Viral Hepatitis puts millions of Americans' health and well-being at risk," the National Viral Hepatitis Roundtable today called on the Administration to work with Congress to take decisive action this year to fix the funding failure for viral hepatitis screening, surveillance, and early intervention programs.

17 Mar 2010

MDS reports revenues of $46M for first-quarter fiscal 2010

MDS Inc., a leading provider of products and services to the global health science markets, today reported financial results and filed its unaudited interim consolidated financial statements and related Management Discussion & Analysis for the three months ended January 31, 2010. In order to simplify our disclosures, we have discontinued the use of non-GAAP measures such as adjusted EBITDA.

16 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

Provectus Pharmaceuticals receives $7.5M in private placement offering

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Endoscopic and surgical treatment of GV bleeding: MDCTPV could provide valuable references

Gastric varices (GV) are an important complication of portal hypertension. As an almost atraumatic method, computed tomography (CT) angiography has been used widely to show the portal vein system. However, the collateral circulation of GV in different locations has been reported only rarely.

6 Mar 2010

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

Alcoholic liver disease (ALD) is the most common cause of liver cirrhosis in the Western world. Liver biopsy is currently considered the gold standard for assessing hepatic fibrosis or cirrhosis in these patients. However, it is an invasive procedure, with rare but potentially life-threatening complications and its accuracy is limited due to sampling error. Transient elastography (FibroScan-, FS) is a novel rapid and noninvasive method to assess liver fibrosis via measurement of liver stiffness (LS).

6 Mar 2010

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

6 Mar 2010

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically increased in health care institutions for inappropriate indications, route of administration and length of treatment. This is associated with an increased cost burden, increased risk of IV related infections, and utilization of hospital resources.

6 Mar 2010

Postoperative complications more likely to occur at low-volume institutions

The frequency of post-operative complications following surgery for liver cancer is associated with a hospital having a low volume of liver surgery. Investigators at The Cancer Institute of New Jersey (CINJ) are presenting that finding at the 63rd Annual Society of Surgical Oncology Symposium taking place this week in St. Louis. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Mar 2010

Liver Cancer News and Research

Further Reading

Study finds colonoscopy safe for Chinese children

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Standard HCV therapy less effective in urban minority patients: Study

New therapies increase survival rates in post-transplant liver cancer patients

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Researchers find some similarities between SPN and PET

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

MDS reports revenues of $46M for first-quarter fiscal 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals receives $7.5M in private placement offering

Development of promising new cancer therapies: OICR announces $1M investment

Endoscopic and surgical treatment of GV bleeding: MDCTPV could provide valuable references

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Postoperative complications more likely to occur at low-volume institutions

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News